Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant: Maternal and Child Health

Université de Montréal

$97,000.00

Asthma, use of controller therapy during pregnancy and perinatal outcomes

FY 2008-09

Summary
The prevalence of asthma among pregnant women is between 4 to 7% and is known as one of the most frequent chronic diseases encountered during pregnancy. Concerns about teratogenicity of asthma medications during pregnancy might lead women to stop or reduce their use of controller therapy, but this fear must be balanced against the risk of loss of asthma control and exacerbations. Lack of oxygen to the foetus can lead to perinatal mortality, intrauterine growth retardation, and preterm birth. Inhaled corticosteroids is the controller therapy of choice during pregnancy and its discontinuation may be one of the most important reasons leading to uncontrolled asthma during pregnancy. Evidence on the association between asthma control through the use of controller therapies during pregnancy and the prevention of adverse perinatal outcomes is scarce. We plan to reconstruct a large cohort of pregnancies from asthmatic women from the linkage of three databases: Régie de l'assurance-maladie (RAMQ) database which provides medical service and prescription claims data, MED-ECHO database which provides hospitalization data and the birth and death registries. This cohort of pregnancies will be used to investigate whether or not there is an association between the dose of inhaled corticosteroids used during pregnancy and the risk of small for gestational age babies, low birth weight babies and preterm delivery. The use of inhaled corticosteroids during pregnancy will be measured with medication claims data recorded in the RAMQ databases. This study will allow us to evaluate whether or not inhaled corticosteroids taken at moderate to high doses during pregnancy are safe for the fetus.
Program
Operating Grant: Maternal and Child Health
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
173037
Name
Blais Lucie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Maternal and Child Health: Secondary Analysis of Provincial and National Databases
Projecttitle
Asthma, use of controller therapy during pregnancy and perinatal outcomes
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$97,000
Cihrequipment2
$3,000
Programname2
Operating Grant: Maternal and Child Health
Keyworddelim
Administrative Databases; Asthma; Controller Therapy; Inhaled Corticosteroids; Low Birth Weight; Pregnancy; Preterm Birth; Small For Gestational Age Babies
Abstract
The prevalence of asthma among pregnant women is between 4 to 7% and is known as one of the most frequent chronic diseases encountered during pregnancy. Concerns about teratogenicity of asthma medications during pregnancy might lead women to stop or reduce their use of controller therapy, but this fear must be balanced against the risk of loss of asthma control and exacerbations. Lack of oxygen to the foetus can lead to perinatal mortality, intrauterine growth retardation, and preterm birth. Inhaled corticosteroids is the controller therapy of choice during pregnancy and its discontinuation may be one of the most important reasons leading to uncontrolled asthma during pregnancy. Evidence on the association between asthma control through the use of controller therapies during pregnancy and the prevention of adverse perinatal outcomes is scarce. We plan to reconstruct a large cohort of pregnancies from asthmatic women from the linkage of three databases: Régie de l'assurance-maladie (RAMQ) database which provides medical service and prescription claims data, MED-ECHO database which provides hospitalization data and the birth and death registries. This cohort of pregnancies will be used to investigate whether or not there is an association between the dose of inhaled corticosteroids used during pregnancy and the risk of small for gestational age babies, low birth weight babies and preterm delivery. The use of inhaled corticosteroids during pregnancy will be measured with medication claims data recorded in the RAMQ databases. This study will allow us to evaluate whether or not inhaled corticosteroids taken at moderate to high doses during pregnancy are safe for the fetus.
Competitiondate
200809
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Blais, Lucie
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Human Dev &Child &Yth~ $97,000~ $3,000~
Université de Montréal - $97,000 Grant (2008-09) | Canada Spends